Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularizaton agent, evaluated in phase I clinical trial

Barbara D. Wamil, Gary B. Thurman, Hakan W. Sundell, Russell F. DeVore, Gail Wakefield, David H. Johnson, Yue Fen Wang, Carl G. Hellerqvist